Annexin Pharmaceuticals AB (publ) (ANNX.ST)

Annexin Pharmaceuticals AB (publ) (ANNX.ST) — VMCI valuation read

ANNX.ST screens at VMCI 42/100, a 8-point gap below the Healthcare sector median (50). For a mid-cap Annexin Pharmaceuticals AB (publ) share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

ANNX.ST has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: ANNX.ST trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.5x leaves covenant headroom, which sets the rate-cycle exposure for Annexin Pharmaceuticals AB (publ).

ANNX.ST fell 1.6% over the trailing 7 days, with a -11.2% read on a 30-day basis.